These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38566191)

  • 1. EP300-ZNF384 transactivates IL3RA to promote the progression of B-cell acute lymphoblastic leukemia.
    Hou Z; Ren Y; Zhang X; Huang D; Yan F; Sun W; Zhang W; Zhang Q; Fu X; Lang Z; Chu C; Zou B; Gao B; Jin B; Kang Z; Liu Q; Yan J
    Cell Commun Signal; 2024 Apr; 22(1):211. PubMed ID: 38566191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EP300-ZNF384 fusion gene product up-regulates GATA3 gene expression and induces hematopoietic stem cell gene expression signature in B-cell precursor acute lymphoblastic leukemia cells.
    Yaguchi A; Ishibashi T; Terada K; Ueno-Yokohata H; Saito Y; Fujimura J; Shimizu T; Ohki K; Manabe A; Kiyokawa N
    Int J Hematol; 2017 Aug; 106(2):269-281. PubMed ID: 28378055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of EP300-ZNF384 fusion in patients with acute lymphoblastic leukemia using RNA fusion gene panel sequencing.
    Jing Y; Li YF; Wan H; Liu DH
    Ann Hematol; 2020 Nov; 99(11):2611-2617. PubMed ID: 32980888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis of Clinical Characteristics of Acute B Lymphoblastic Leukemia with EP300-ZNF384 Fusion Gene Positive].
    Yao ZL; Li YF; Li M; Li Y; Li WJ; Li HH; Liu YY; Lin SH; Li FW; Zhang J; Jing Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):24-28. PubMed ID: 32027248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP.
    Qian M; Zhang H; Kham SK; Liu S; Jiang C; Zhao X; Lu Y; Goodings C; Lin TN; Zhang R; Moriyama T; Yin Z; Li Z; Quah TC; Ariffin H; Tan AM; Shen S; Bhojwani D; Hu S; Chen S; Zheng H; Pui CH; Yeoh AE; Yang JJ
    Genome Res; 2017 Feb; 27(2):185-195. PubMed ID: 27903646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of a Cryptic EP300/ZNF384 Gene Fusion by Chromosomal Microarray and Next-Generation Sequencing Studies in a Pediatric Patient with B-Lymphoblastic Leukemia.
    Berg HE; Blackburn PR; Smadbeck JB; Swanson KE; Rice CS; Webley MR; Johnson SH; Vasmatzis G; Xu X; Greipp PT; Hoppman NL; Ketterling RP; Baughn LB; Boston CH; Sutton LM; Peterson JF
    Lab Med; 2021 May; 52(3):297-302. PubMed ID: 33145596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression.
    McClure BJ; Heatley SL; Kok CH; Sadras T; An J; Hughes TP; Lock RB; Yeung D; Sutton R; White DL
    Br J Cancer; 2018 Apr; 118(7):1000-1004. PubMed ID: 29531323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ZNF384-fusion proteins have high affinity for the transcriptional coactivator EP300 and aberrant transcriptional activities.
    Yamamoto H; Hayakawa F; Yasuda T; Odaira K; Minamikawa Y; Tange N; Hirano D; Kojima Y; Morishita T; Tsuzuki S; Naoe T; Kiyoi H
    FEBS Lett; 2019 Aug; 593(16):2151-2161. PubMed ID: 31234226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype.
    Hirabayashi S; Ohki K; Nakabayashi K; Ichikawa H; Momozawa Y; Okamura K; Yaguchi A; Terada K; Saito Y; Yoshimi A; Ogata-Kawata H; Sakamoto H; Kato M; Fujimura J; Hino M; Kinoshita A; Kakuda H; Kurosawa H; Kato K; Kajiwara R; Moriwaki K; Morimoto T; Nakamura K; Noguchi Y; Osumi T; Sakashita K; Takita J; Yuza Y; Matsuda K; Yoshida T; Matsumoto K; Hata K; Kubo M; Matsubara Y; Fukushima T; Koh K; Manabe A; Ohara A; Kiyokawa N;
    Haematologica; 2017 Jan; 102(1):118-129. PubMed ID: 27634205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency and outcome of pediatric acute lymphoblastic leukemia with ZNF384 gene rearrangements including a novel translocation resulting in an ARID1B/ZNF384 gene fusion.
    Shago M; Abla O; Hitzler J; Weitzman S; Abdelhaleem M
    Pediatr Blood Cancer; 2016 Nov; 63(11):1915-21. PubMed ID: 27392123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zinc finger protein 384 (
    Sudutan T; Erbilgin Y; Hatirnaz Ng O; Karaman S; Karakas Z; Kucukcankurt F; Celkan T; Timur C; Ozdemir GN; Hacısalihoglu S; Gelen SA; Sayitoğlu M
    Leuk Lymphoma; 2022 Dec; 63(12):2931-2939. PubMed ID: 35921545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment and genetic characterization of a novel mixed-phenotype acute leukemia cell line with EP300-ZNF384 fusion.
    Ping N; Qiu H; Wang Q; Dai H; Ruan C; Ehrentraut S; Drexler HG; MacLeod RA; Chen S
    J Hematol Oncol; 2015 Aug; 8():100. PubMed ID: 26293203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ZNF384-Related Fusion Genes in Acute Lymphoblastic Leukemia.
    Zhu L; Bai W; Cheng Q; Fang J
    Cancer Control; 2023; 30():10732748231182787. PubMed ID: 37306722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel recurrent EP300-ZNF384 gene fusion in B-cell precursor acute lymphoblastic leukemia.
    Gocho Y; Kiyokawa N; Ichikawa H; Nakabayashi K; Osumi T; Ishibashi T; Ueno H; Terada K; Oboki K; Sakamoto H; Shioda Y; Imai M; Noguchi Y; Arakawa Y; Kojima Y; Toyama D; Hata K; Yoshida T; Matsumoto K; Kato M; Fukushima T; Koh K; Manabe A; Ohara A;
    Leukemia; 2015 Dec; 29(12):2445-8. PubMed ID: 25943178
    [No Abstract]   [Full Text] [Related]  

  • 15. A Rare Case Report of B-Cell Acute Lymphoblastic Leukemia with EP300::ZNF384 Fusion Gene.
    Wu X; Yang X; Chen Y; Zhang Z; XinhongYang
    Clin Lab; 2024 Jun; 70(6):. PubMed ID: 38868890
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunophenotypic characteristics of ZNF384 rearrangement compared with BCR-ABL1, KMT2A rearrangement, and other adult B-cell precursor acute lymphoblastic leukemia.
    Wang YZ; Qin YZ; Chang Y; Yuan XY; Chen WM; He LL; Hao L; Shi WH; Jiang Q; Jiang H; Huang XJ; Liu YR
    Cytometry B Clin Cytom; 2022 Sep; 102(5):360-369. PubMed ID: 35735203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic application of fluorescence in situ hybridization and immunophenotype profile for the identification of ZNF384 gene rearrangements in B cell acute lymphoblastic leukemia.
    Janet NB; Kulkarni U; Arun AK; Bensega B; Devasia AJ; Korula A; Abraham A; George B; Mathews V; Balasubramanian P
    Int J Lab Hematol; 2021 Aug; 43(4):658-663. PubMed ID: 33988307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemia.
    Zhao X; Wang P; Diedrich JD; Smart B; Reyes N; Yoshimura S; Zhang J; Yang W; Barnett K; Xu B; Li Z; Huang X; Yu J; Crews K; Yeoh AEJ; Konopleva M; Wei CL; Pui CH; Savic D; Yang JJ
    Nat Commun; 2022 Sep; 13(1):5401. PubMed ID: 36104354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical characteristics and outcomes of childhood B-ALL with ZNF384 and MEF2D rearrangements].
    Hirabayashi S; Manabe A; Ohki K; Kiyokawa N
    Rinsho Ketsueki; 2023; 64(7):633-638. PubMed ID: 37544723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ZNF384 fusion transcript levels for measurable residual disease monitoring in adult B-cell acute lymphoblastic leukemia.
    Shi ZY; Wang X; Chen WM; Li LD; Hao Y; Li JY; Sun K; Zhao XS; Jiang H; Jiang Q; Huang XJ; Qin YZ
    Hematol Oncol; 2024 Jan; 42(1):e3251. PubMed ID: 38287528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.